Development and evaluation of in vivo tissue engineered blood vessels in a porcine model

Rothuizen, T.C.; Damanik, Febriyani; Lavrijsen, T.; Visser, Michel J.T.; Hamming, Jaap F.; Lalai, Reshma; Duijs, Jacques M.G.J.; Zonneveld, Anton Jan van; Hoefer, Imo E.; Blitterswijk, Clemens A. van; Rabelink, Ton J.; Moroni, Lorenzo; Rotmans, Joris I.

doi:10.1016/j.biomaterials.2015.10.023

Cited by 74 publications

(64 citation statements)

References 48 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SMC’s are important in maintaining vascular homeostasis notably with regard to the vasoreactivity of vessels. Various studies have shown that after grafting, populations of (myo-)fibroblasts have either transdifferentiated to, of been replaced by SMC like cells [14, 58, 59, 66]. A histological overview of the differentiation of the tissue capsules towards blood vessel-like structures that we observed in our pig studies is provided in Figure 3.…”

Section: Remodeling Of Tebv After Implantation In the Circulationmentioning

confidence: 72%

“…Monolayer of endothelium. Elastin like mesh seen.1085 mmHgIntroduction sheeth usedInteresting presence of elastinYamanami et al [71]Type C – mold systemDorsum - subcutaneousArgatroban610 mmFemale BeaglesFemoral artery end-to-endultrasonographyOriginal: biotube 33%Type C: 100%7 daysFibroblasts and collagen.Elastin present.Thick, collagen rich, elastin present.Original: biotube 944 mmHgType C: 1825 mmHgImprovement over original designFurukoshi et al [15]Silicone, fasciaMedial thigh - subcutaneousFascia covered1510 mmFemale Japanese white rabbitsFemoral artery end-to-endMilking test60%80%80%2 weeks5 weeks8 weeks-Fibroblast, endothelium ingrowth.-Interesting concept to incorporate dorsal fasciaTsukagoshi et al [16]PEOT/PBT 55/45Abdomen - subcutaneousChloroform etching880 mmFemale landrace pigsCarotid artery bilateral, end-to-endAngiography88%4 weeks(myo-)fibroblasts, ECM, some luminal macrophages.Predominantly desmin (+) SMC like cells, no leukocytes, Monolayer of endothelium, some elastin positivity.5211,04 mmHg (derived burst pressure)Biomaterial surface modification to tailor FBRRothuizen et al [14]α- SMA, alpha-smooth muscle actin; SMC, smooth muscle cell; vim, vimentin; des, desmin; FBR, foreign body response …”

Section: Overview Of Approaches For In Situ Vascular Tissue Engineeringmentioning

confidence: 99%

“…Campbell et al already showed an elegant approach to this problem by lining the luminal side of the TEBV with autologous mesothelial cells [58]. Despite the difficulty of seeding an endothelium upon TEBV’s prior to grafting, all studies using the in vivo grafts have shown endothelialization of the lumen [14, 16, 59, 71]. Although, the function of endothelial progenitor cells is decreased in patients with chronic kidney disease [76].…”

Section: Remodeling Of Tebv After Implantation In the Circulationmentioning

confidence: 99%

“…Before grafting α-SMA, vimentin positive (myo-)fibroblasts are present, with frequent CD-45 positive leucocytes and no endothelium (lectin negativity). After grafting the cells are α-SMA, desmin positive SMC like cells with no CD-45 positive cells and an endothelial monolayer [14] …”

Section: Remodeling Of Tebv After Implantation In the Circulationmentioning

confidence: 99%

“…Interestingly, most biomedical research concerning the foreign body response (FBR) is conducted with the aim of minimizing, or abolishing the cascade resulting in this host reaction, as propagation of the FBR is commonly associated with a decrease in implant functionality [12, 13 ]. Yet, by utilizing the FBR to generate tissue constructs in a controlled setting, various groups have developed methods to construct TEBV’s [14–17]. This involves an implantable biomaterial, which elicits a FBR to allow the growth of tissue around it (Figure 1.).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Utilizing the Foreign Body Response to Grow Tissue Engineered Blood Vessels in Vivo

Geelhoed

Moroni

Rotmans

2017

J. of Cardiovasc. Trans. Res.

Self Cite

View full text Add to dashboard Cite

It is well known that the number of patients requiring a vascular grafts for use as vessel replacement in cardiovascular diseases, or as vascular access site for hemodialysis is ever increasing. The development of tissue engineered blood vessels (TEBV’s) is a promising method to meet this increasing demand vascular grafts, without having to rely on poorly performing synthetic options such as polytetrafluoroethylene (PTFE) or Dacron. The generation of in vivo TEBV’s involves utilizing the host reaction to an implanted biomaterial for the generation of completely autologous tissues. Essentially this approach to the development of TEBV’s makes use of the foreign body response to biomaterials for the construction of the entire vascular replacement tissue within the patient’s own body. In this review we will discuss the method of developing in vivo TEBV’s, and debate the approaches of several research groups that have implemented this method.

show abstract

Section: Remodeling Of Tebv After Implantation In the Circulationmentioning

confidence: 72%

Section: Overview Of Approaches For In Situ Vascular Tissue Engineeringmentioning

confidence: 99%

Section: Remodeling Of Tebv After Implantation In the Circulationmentioning

confidence: 99%

Section: Remodeling Of Tebv After Implantation In the Circulationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Utilizing the Foreign Body Response to Grow Tissue Engineered Blood Vessels in Vivo

Geelhoed

Moroni

Rotmans

2017

J. of Cardiovasc. Trans. Res.

Self Cite

View full text Add to dashboard Cite

show abstract

Control Delivery of Multiple Growth Factors to Actively Steer Differentiation and Extracellular Matrix Protein Production

et al. 2021

Self Cite

View full text Add to dashboard Cite

In tissue engineering, biomaterials have been used to steer the host response. This determines the outcome of tissue regeneration, which is modulated by multiple growth factors (GFs). Hence, a sustainable delivery system for GFs is necessary to control tissue regeneration actively. A delivery technique of single and multiple GF combinations, using a layer‐by‐layer (LBL) procedure to improve tissue remodeling, is developed. TGF‐β1, PDGF‐ββ, and IGF‐1 are incorporated on tailor‐made polymeric rods, which could be used as a tool for potential tissue engineering applications, such as templates to induce the formation of in situ tissue engineered blood vessels (TEBVs). Cell response is analyzed in vitro using rat and human dermal fibroblasts for cellular proliferation, fibroblast differentiation, and extracellular matrix (ECM) protein synthesis. Results revealed a higher loading efficiency and control release of GFs incorporated on chloroform and oxygen plasma‐activated (COX) rods. Single PDGF‐ββ and IGF‐1 release, and dual release with TGF‐β1 from COX rods, showed higher cell proliferation when compared to COX rods alone. A substantial increase in α‐smooth muscle actin (α‐SMA) is also observed in GF releasing COX rods, with TGF‐β1 COX rods providing the most pronounced differentiation. A significant increase in collagen and elastin synthesis is observed on all GF releasing COX rods compared to control, with COX rods releasing TGF‐β1 and IGF‐1 providing the highest secretion. TGF‐β1 and IGF‐1 releasing COX rods induced higher Glycosaminoglycan (GAG)/DNA amounts than the other GF releasing COX rods. As PDGF‐ββ and TGF‐β1/PDGF‐ββ COX rods displayed the highest fibroblast attachment, these rods provided the highest total collagen and elastin production. The attractive results from efficiently incorporating single and multiple GFs on COX rods and their sustainable release to steer cellular behavior suggest a promising route to enrich the formation of in situ engineered tissues.

show abstract

Tissue‐Engineered Vascular Grafts: Emerging Trends and Technologies

Gupta

Mandal

2021

Adv Funct Materials

View full text Add to dashboard Cite

Vascular tissue engineering has made prodigious progress in recent years by converging multidisciplinary approaches. Latest technological advancements foster the development of next‐generation tissue‐engineered vascular grafts (TEVGs) for treating various vasculopathies. While traditional therapeutic methods rely on bypassing the severely damaged vessels with synthetic counterparts with no growth potential, contemporary perspectives focus on biodegradable conduits bestowing an inherent remodeling capability. This review highlights emerging innovative trends and technologies adopted to pragmatically fulfill current scientific needs while improving overall TEVG performance in pre‐clinical and clinical settings. A comprehensive overview of various milestones achieved in the past few decades is first summarized, followed by an appraisal of the significant hurdles for clinical translation. The latest techniques to rationally address critical challenges, viz., intimal hyperplasia, thrombosis, constructive graft remodeling, and adequate neo‐tissue formation are discussed. Finally, an update on ongoing clinical trials is provided and future perspectives required to persuade TEVGs to become a clinical reality are delineated.

show abstract

Development and evaluation of in vivo tissue engineered blood vessels in a porcine model

Abstract: Autologous TEBVs were created in vivo with sufficient mechanical strength enabling vascular grafting. Grafts differentiated towards a vascular phenotype upon grafting.

Cited by 74 publications

References 48 publications

Utilizing the Foreign Body Response to Grow Tissue Engineered Blood Vessels in Vivo

Utilizing the Foreign Body Response to Grow Tissue Engineered Blood Vessels in Vivo

Control Delivery of Multiple Growth Factors to Actively Steer Differentiation and Extracellular Matrix Protein Production

Tissue‐Engineered Vascular Grafts: Emerging Trends and Technologies

Contact Info

Product

Resources

About